BRPI0820162A2 - composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids - Google Patents

composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids

Info

Publication number
BRPI0820162A2
BRPI0820162A2 BRPI0820162A BRPI0820162A BRPI0820162A2 BR PI0820162 A2 BRPI0820162 A2 BR PI0820162A2 BR PI0820162 A BRPI0820162 A BR PI0820162A BR PI0820162 A BRPI0820162 A BR PI0820162A BR PI0820162 A2 BRPI0820162 A2 BR PI0820162A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
treatment
onset
aids
delay
Prior art date
Application number
BRPI0820162A
Other languages
English (en)
Portuguese (pt)
Inventor
T Sisko John
Anthony Neville
Gomez Robert
Tynebor Robert
M Jolly Samson
J Tucker Thomas
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BRPI0820162A2 publication Critical patent/BRPI0820162A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0820162A 2007-11-20 2008-11-14 composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids BRPI0820162A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US376907P 2007-11-20 2007-11-20
PCT/US2008/012774 WO2009067166A2 (en) 2007-11-20 2008-11-14 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0820162A2 true BRPI0820162A2 (pt) 2019-09-24

Family

ID=40336474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820162A BRPI0820162A2 (pt) 2007-11-20 2008-11-14 composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids

Country Status (12)

Country Link
US (1) US8404856B2 (enExample)
EP (1) EP2222661B1 (enExample)
JP (1) JP5539216B2 (enExample)
KR (1) KR20100088142A (enExample)
CN (1) CN101952274A (enExample)
AU (1) AU2008326784B2 (enExample)
BR (1) BRPI0820162A2 (enExample)
CA (1) CA2705834A1 (enExample)
IL (1) IL205386A0 (enExample)
MX (1) MX2010005483A (enExample)
RU (1) RU2010125220A (enExample)
WO (1) WO2009067166A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026075A1 (en) * 2008-09-04 2010-03-11 F. Hoffmann-La Roche Ag Pyridine derivatives as inhibitors of hiv-i reverse transcriptase
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
PL2924034T3 (pl) * 2010-03-30 2017-07-31 Merck Canada Inc. Kompozycja farmaceutyczna zawierająca nienukleozydowy inhibitor odwrotnej transkryptazy
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor
WO2014052171A1 (en) * 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CA2892919A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
EP3077376B1 (en) * 2013-12-04 2019-10-16 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
EP3785714A1 (en) * 2014-04-01 2021-03-03 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
MX391226B (es) * 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
EP3377493B1 (en) 2015-11-20 2020-04-08 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
EP3898595B1 (en) * 2018-12-18 2024-05-01 Merck Sharp & Dohme LLC Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
CA3141143A1 (en) * 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Pyridinone derivatives as selective cytotoxic agents against hiv infected cells
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN112876409A (zh) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
ES2176251T3 (es) * 1993-07-28 2002-12-01 Aventis Pharma Ltd Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
CA2330304A1 (en) * 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6800651B2 (en) * 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
WO2002024650A2 (en) * 2000-09-19 2002-03-28 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
PL227577B1 (pl) * 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
US20050014774A1 (en) * 2003-04-28 2005-01-20 Richard Storer Oxo-pyrimidine compounds
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CN1946680B (zh) 2004-04-23 2011-04-06 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
EP1831157A2 (en) * 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101287702A (zh) 2005-10-19 2008-10-15 弗·哈夫曼-拉罗切有限公司 N-苯基苯乙酰胺非核苷逆转录酶抑制剂
EP1940781A1 (en) * 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
WO2008098143A2 (en) * 2007-02-08 2008-08-14 Trius Therapeutics Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
WO2009067166A3 (en) 2009-07-16
AU2008326784B2 (en) 2014-04-24
MX2010005483A (es) 2010-06-11
RU2010125220A (ru) 2011-12-27
US8404856B2 (en) 2013-03-26
KR20100088142A (ko) 2010-08-06
JP5539216B2 (ja) 2014-07-02
IL205386A0 (en) 2010-12-30
US20100256181A1 (en) 2010-10-07
JP2011503230A (ja) 2011-01-27
CN101952274A (zh) 2011-01-19
EP2222661A2 (en) 2010-09-01
WO2009067166A2 (en) 2009-05-28
CA2705834A1 (en) 2009-05-28
AU2008326784A1 (en) 2009-05-28
EP2222661B1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
WO2008115281A3 (en) Compounds for treating viral infections
IL269370B (en) Chemicals, preparations and methods for the treatment and prevention of orthopoxvirus infections and related diseases
WO2008127364A3 (en) Antiviral compounds and use thereof
BRPI1007379A2 (pt) composições e métodos para o tratamento ou a prevenção de infecções orais por e. coli
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BRPI0806686A2 (pt) Compostos e seus usos, métodos de tratamento ou prevenção, composições farmacêuticas e composto e solvato cristalinos
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
PT2109602E (pt) Derivados de tetraciclina para o tratamento de infecções bacterianas, virais e parasitárias
BRPI1012951A2 (pt) "administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
BR112013013435A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto.
BRPI0813001A2 (pt) composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica
EP1868628A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING POCKET VIRUS INFECTIONS
CL2007003645A1 (es) Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
IL202450A (en) Pharmaceutical composition to treat influenza virus infection
BRPI0814300A2 (pt) Composto, composição farmacêutica, e, método para tratar uma infecção viral
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.